Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Contact
103 Carnegie Center Drive
Suite 300
PrincetonNJ08852
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29
Stocks News & Analysis
stocks
Shares leap for ASX rare earths provider
We increased our fair value based on higher expected rare earths pricing.
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,851.40 | 29.00 | -0.33% |
| CAC 40 | 7,979.63 | 62.18 | -0.77% |
| DAX 40 | 23,507.77 | 132.26 | -0.56% |
| Dow JONES (US) | 46,872.44 | 544.83 | -1.15% |
| FTSE 100 | 10,290.75 | 63.02 | -0.61% |
| HKSE | 25,716.76 | 182.00 | -0.70% |
| NASDAQ | 22,406.39 | 309.74 | -1.36% |
| Nikkei 225 | 54,452.96 | 572.41 | -1.04% |
| NZX 50 Index | 13,199.29 | 93.84 | -0.71% |
| S&P 500 | 6,701.13 | 74.67 | -1.10% |
| S&P/ASX 200 | 8,629.00 | 14.20 | -0.16% |
| SSE Composite Index | 4,129.10 | 4.33 | -0.10% |